Sun Pharmaceutical Industries Ltd. has announced their unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2023, as well as a composite scheme of arrangement for the amalgamation of five wholly-owned subsidiaries with the company and reclassification of general reserves into retained earnings.